Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 20/20 | 0.67 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | RAF1 | P04049 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | YES1 | P07947 | 1/20 | 0.53 |
| ▸ | RET | P07949 | 1/20 | 0.53 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.53 |
| ▸ | TEK | Q02763 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1013858 | 0.94 | BRAF (0.70) | BRAFABL1EGFRRAF1LCK | |
| SCHEMBL3496951 | 0.94 | BRAF (0.70) | BRAFABL1EGFRRAF1LCK | |
| SCHEMBL1016721 | 0.91 | BRAF (0.80) | BRAFABL1EGFRRAF1LCK | |
| SCHEMBL3497135 | 0.91 | BRAF (0.63) | BRAFABL1EGFRRAF1LCK | |
| SCHEMBL3497104 | 0.91 | BRAF (0.80) | BRAFABL1EGFRRAF1LCK | |
| SCHEMBL1016289 | 0.91 | BRAF (0.80) | BRAFABL1EGFRRAF1LCK | |
| SCHEMBL3497343 | 0.87 | BRAF (0.64) | BRAFABL1EGFRRAF1LCK | |
| SCHEMBL4052212 | 0.85 | BRAF (0.81) | BRAFABL1EGFRRAF1LCK | |
| SCHEMBL1014044 | 0.85 | BRAF (0.81) | BRAFABL1EGFRRAF1LCK | |
| SCHEMBL3496952 | 0.85 | BRAF (0.67) | BRAFABL1EGFRRAF1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029657-A1 | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof | WYETH (US) | 2010-02-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029657-A1 | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof | BRAF, RAF1, ARAF | BRAF 1/4885ABL1 392/4885EGFR 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.